ArticleThe Journal of clinical investigation2007
A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo.
Article in The Journal of clinical investigation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 79 citations in OpenAlex.
- P53 and the Ultraviolet Radiation-Induced Skin Response: Finding the Light in the Darkness of Triggered Carcinogenesis.Cancers · 2024Review
- Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer.International journal of molecular sciences · 2024Review
- SMG1 and CDK12 Link ΔNp63α Phosphorylation to RNA Surveillance in Keratinocytes.Journal of proteome research · 2021Article
- Tetrafunctional Block Copolymers Promote Lung Gene Transfer in Newborn Piglets.Molecular therapy. Nucleic acids · 2019Article
- 2-anilino-4-amino-5-aroylthiazole-type compound AS7128 inhibits lung cancer growth through decreased iASPP and p53 interaction.Cancer science · 2018Article
- P53-derived hybrid peptides induce apoptosis of synovial fibroblasts in the rheumatoid joint.Oncotarget · 2017Article
- Sertad1 antagonizes iASPP function by hindering its entrance into nuclei to interact with P53 in leukemic cells.BMC cancer · 2017Article
- Recombinant adeno-associated virus expressing a p53-derived apoptotic peptide (37AA) inhibits HCC cells growth in vitro and in vivo.Oncotarget · 2017Article
- p73 engages A2B receptor signalling to prime cancer cells to chemotherapy-induced death.Oncogene · 2015Article
- Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.Cancer research · 2015Article
- A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity.Cell death & disease · 2015Article
- Loss of autophagy causes a synthetic lethal deficiency in DNA repair.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.Cell death & disease · 2014Article
- The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry.Biomarkers in cancer · 2013Review
- Structural basis for ASPP2 recognition by the tumor suppressor p73.Journal of molecular biology · 2012Article
- Graft-versus-host disease-related cytokine-driven apoptosis depends on p73 in cytokeratin 15-positive target cells.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012Article
- Inhibition of autophagy impairs tumor cell invasion in an organotypic model.Cell cycle (Georgetown, Tex.) · 2012Article
- DRAM-1 encodes multiple isoforms that regulate autophagy.Autophagy · 2012Article
- p73 as a pharmaceutical target for cancer therapy.Current pharmaceutical design · 2011Review
- Pharmacological activation of p53 in cancer cells.Current pharmaceutical design · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor suppressor p53 is a potent inducer of tumor cell death, and strategies exist to exploit p53 for therapeutic gain. However, because about half of human cancers contain mutant p53, application of these strategies is restricted. p53 family members, in particular p73, are in many ways functional paralogs of p53, but are rarely mutated in cancer. Methods for specific activation of p73, however, remain to be elucidated. We describe here a minimal p53-derived apoptotic peptide that induced death in multiple cell types regardless of p53 status. While unable to activate gene expression directly, this peptide retained the capacity to bind iASPP - a common negative regulator of p53 family members. Concordantly, in p53-null cells, this peptide derepressed p73, causing p73-mediated gene activation and death. Moreover, systemic nanoparticle delivery of a transgene expressing this peptide caused tumor regression in vivo via p73. This study therefore heralds what we believe to be the first strategy to directly and selectively activate p73 therapeutically and may lead to the development of broadly applicable agents for the treatment of malignant disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.